NVS:BCBA
Novartis CEDEAR
10Ā 800,00Ā ARS
0,00%
(0,00) 1 p
19. apr, 16:40:36 GMT ā3 · ARS
search
KƵik sĆ¼mbolid
1 p
5 p
1 kuu
6 kuud
YTD
1 a
5 a
MAX
| SĆ¼mbol | Hind | Muutus | % muutus |
|---|
insights_autoĆksuse NVS pƵhistatistika genereerimineā¦
Turu kapit.
297,38Ā mld
Maht
0,00
KƤibivad aktsiad
2,03Ā mld
Tƶƶtajate arv
75Ā tuh
Uudised
Erinevatest veebiallikatest
TradingView
·
1 pƤeva eest
Novartis AG expected to post earnings of $2.00 a share - Earnings Preview
Yahoo Finance
·
1 pƤeva eest
Novartis malaria treatment CoartemĀ® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Endpoints News
·
2 pƤeva eest
Novartis built a big business around delivering radioactive cancer treatments. Can a generic compete?
Profiil
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Teave Ć¼ksuse Novartis CEDEAR kohta
TegevjuhtVasant Narasimhan
Tƶƶtajad75,3Ā tuh
Asutatud29. veebr 1996
PeakontoridBasel, Basel, Å veits
Sektor-
Veebisaitnovartis.com
AI genereeritud sisu vƵib sisaldada vigu. Lisateave